Watch VNOV. Know when insiders buy.
One email the day a filing lands. Free.
VNOV
VitaNova Life Sciences Corp
1.38
+0.00 +0.00%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $11.5MP/E —DIV YIELD —FCF YIELD —REV TTM $3.2M +22.0%NET INCOME −$114K −113.3%NET CASH —52W 0.42 – 7.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jul 31 | $322K | +209.5% | 9.5% | −$122K | −$123K | — | -0.01 | $7K | — | — | Sep 14 |
| Q4 2026 · Apr 30derived | $1.8M | −8.6% | 14.8% | −$110K | $18K | −97.8% | 0.01 | $428K | — | — | Jul 29 |
| Q3 2026 · Jan 31 | $710K | +130.2% | 44.6% | $47K | −$44K | −160.8% | -0.01 | −$90K | — | — | Mar 16 |
| Q2 2026 · Oct 31 | $427K | +46.2% | 61.1% | $99K | $36K | +9.7% | 0.00 | $213K | — | — | Mar 16 |
| Q1 2026 · Jul 31 | $104K | −4.2% | 66.2% | −$32K | −$46K | — | 0.00 | $264K | — | — | Sep 14 |
| Q4 2025 · Apr 30derived | $2M | +258.7% | 59.3% | $1.1M | $800K | +376.6% | 0.02 | $479K | — | — | Jul 29 |
| Q3 2025 · Jan 31 | $308K | +1081.3% | 61.4% | $109K | $73K | +1126.9% | 0.01 | $209K | — | — | Mar 16 |
| Q2 2025 · Oct 31 | $292K | — | 53.3% | $63K | $33K | — | 0.00 | $9K | — | — | Mar 16 |
| Q1 2025 · Jul 31 | $108K | — | 67.5% | −$45K | −$55K | — | 0.00 | −$504K | — | — | Mar 16 |
| Q4 2024 · Apr 30derived | $545K | — | 64.6% | $233K | $168K | — | 0.01 | −$191K | — | — | Jul 24 |
| Q3 2024 · Jan 31 | $26K | — | 100.0% | $6K | $6K | — | 0.00 | −$151K | — | — | Mar 17 |
| Q2 2024 · Oct 31 | $0 | — | — | −$9K | −$9K | — | 0.00 | −$8K | — | — | Mar 17 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 30 | $3M | 30.1% | $4K | −$37K | -1.2% | -0.00 | $814K | — | — | — | — |
| FY2025 · to Apr 30 | $2.7M | 59.2% | $1.2M | $851K | 32.0% | 0.03 | $193K | — | — | — | — |
| FY2024 · to Apr 30 | $571K | 66.2% | $206K | $141K | 24.7% | 0.01 | −$376K | — | — | — | — |
| FY2023 · to Apr 30 | $38K | 100.0% | −$24K | −$24K | -63.8% | 0.00 | −$18K | — | — | — | — |
| FY2022 · to Apr 30 | $120K | — | −$13K | $140K | 116.4% | 0.02 | $4K | — | — | — | — |
| FY2021 · to Apr 30 | $0 | — | −$52K | −$52K | — | -0.01 | −$42K | — | — | — | — |
Every number comes from VitaNova Life Sciences Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.